Emerging treatment options for patients with high-risk myelodysplastic syndrome

Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis with peripheral blood cytopenias, dysplastic cell morphology, and a variable risk of progression to acute myeloid leukemia (AML). The hypomethylating agents (HMA) azacitidine and d...

Descripción completa

Detalles Bibliográficos
Autores principales: Bewersdorf, Jan Philipp, Carraway, Hetty, Prebet, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675905/
https://www.ncbi.nlm.nih.gov/pubmed/33240476
http://dx.doi.org/10.1177/2040620720955006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675905/
https://www.ncbi.nlm.nih.gov/pubmed/33240476
http://dx.doi.org/10.1177/2040620720955006

Ejemplares similares